New developments in atherosclerosis: Clinical potential of PCSK9 inhibition

Medicine & Life Sciences

• Subtilisin 100%
• Atherosclerosis 56%
• Proteins 25%
• Monoclonal Antibodies 21%
• LDL Receptors 20%
• evolocumab 19%
• LDL Lipoproteins 17%
• Names 10%
• alirocumab 9%
• Kinetics 8%
• Gain of Function Mutation 7%
• Loss of Function Mutation 6%
• United States Food and Drug Administration 5%
• Hydroxymethylglutaryl-CoA Reductase Inhibitors 5%
• LDL Cholesterol 5%
• Membrane Proteins 4%
• Pharmacokinetics 4%
• Amino Acids 4%
• Lipids 3%
• Therapeutics 1%

Social Sciences

• loss of function 58%
• tolerance 31%
• medicine 25%
• event 19%
• interaction 16%